AU3224997A - Prodrugs of thalidomide and methods for using same as modulators of t-cell function - Google Patents

Prodrugs of thalidomide and methods for using same as modulators of t-cell function

Info

Publication number
AU3224997A
AU3224997A AU32249/97A AU3224997A AU3224997A AU 3224997 A AU3224997 A AU 3224997A AU 32249/97 A AU32249/97 A AU 32249/97A AU 3224997 A AU3224997 A AU 3224997A AU 3224997 A AU3224997 A AU 3224997A
Authority
AU
Australia
Prior art keywords
thalidomide
prodrugs
modulators
methods
same
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU32249/97A
Inventor
Robert E. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Prototek Inc
Original Assignee
Prototek Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prototek Inc filed Critical Prototek Inc
Publication of AU3224997A publication Critical patent/AU3224997A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06086—Dipeptides with the first amino acid being basic

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU32249/97A 1996-05-29 1997-05-29 Prodrugs of thalidomide and methods for using same as modulators of t-cell function Abandoned AU3224997A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1855896P 1996-05-29 1996-05-29
US60018558 1996-05-29
PCT/US1997/009421 WO1997045117A1 (en) 1996-05-29 1997-05-29 Prodrugs of thalidomide and methods for using same as modulators of t-cell function

Publications (1)

Publication Number Publication Date
AU3224997A true AU3224997A (en) 1998-01-05

Family

ID=21788567

Family Applications (1)

Application Number Title Priority Date Filing Date
AU32249/97A Abandoned AU3224997A (en) 1996-05-29 1997-05-29 Prodrugs of thalidomide and methods for using same as modulators of t-cell function

Country Status (5)

Country Link
EP (1) EP0914123A4 (en)
AU (1) AU3224997A (en)
CA (1) CA2256669A1 (en)
CZ (1) CZ389398A3 (en)
WO (1) WO1997045117A1 (en)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE122010000020I1 (en) 1996-04-25 2010-07-08 Prosidion Ltd Method for lowering the blood glucose level in mammals
DE19823831A1 (en) 1998-05-28 1999-12-02 Probiodrug Ges Fuer Arzneim New pharmaceutical use of isoleucyl thiazolidide and its salts
DE19828114A1 (en) 1998-06-24 2000-01-27 Probiodrug Ges Fuer Arzneim Produgs of unstable inhibitors of dipeptidyl peptidase IV
DE19828113A1 (en) 1998-06-24 2000-01-05 Probiodrug Ges Fuer Arzneim Prodrugs of Dipeptidyl Peptidase IV Inhibitors
DE19834591A1 (en) 1998-07-31 2000-02-03 Probiodrug Ges Fuer Arzneim Use of substances that decrease the activity of dipeptidyl peptidase IV to increase blood sugar levels, e.g. for treating hypoglycemia
US7629360B2 (en) 1999-05-07 2009-12-08 Celgene Corporation Methods for the treatment of cachexia and graft v. host disease
US6613879B1 (en) * 1999-05-14 2003-09-02 Boehringer Ingelheim Pharma Kg FAP-activated anti-tumour compounds
EP1181055A2 (en) 1999-05-14 2002-02-27 Boehringer Ingelheim Pharmaceuticals Inc. Enzyme-activated anti-tumor prodrug compounds
DE19926233C1 (en) 1999-06-10 2000-10-19 Probiodrug Ges Fuer Arzneim Production of thiazolidine, useful as pharmaceutical intermediate, comprises reacting hexamethylenetetramine with cysteamine
DE19940130A1 (en) 1999-08-24 2001-03-01 Probiodrug Ges Fuer Arzneim New effectors of Dipeptidyl Peptidase IV for topical use
PT2055302E (en) 2000-03-31 2014-12-03 Royalty Pharma Collection Trust Method for the improvement of islet signaling in diabetes mellitus and for its prevention
US7132104B1 (en) 2000-10-27 2006-11-07 Probiodrug Ag Modulation of central nervous system (CNS) dipeptidyl peptidase IV (DPIV) -like activity for the treatment of neurological and neuropsychological disorders
US7091353B2 (en) * 2000-12-27 2006-08-15 Celgene Corporation Isoindole-imide compounds, compositions, and uses thereof
DE10106852A1 (en) * 2001-02-14 2002-09-05 T Luger Anti-inflammatory compounds
WO2002068414A2 (en) 2001-02-27 2002-09-06 The Governement Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Analogs of thalidomide as potential angiogenesis inhibitors
US6890905B2 (en) 2001-04-02 2005-05-10 Prosidion Limited Methods for improving islet signaling in diabetes mellitus and for its prevention
DE10150203A1 (en) 2001-10-12 2003-04-17 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitor in treatment of cancer
US7368421B2 (en) 2001-06-27 2008-05-06 Probiodrug Ag Use of dipeptidyl peptidase IV inhibitors in the treatment of multiple sclerosis
US20030130199A1 (en) 2001-06-27 2003-07-10 Von Hoersten Stephan Dipeptidyl peptidase IV inhibitors and their uses as anti-cancer agents
US6844316B2 (en) 2001-09-06 2005-01-18 Probiodrug Ag Inhibitors of dipeptidyl peptidase I
EP1480961B1 (en) 2002-02-28 2006-12-27 Prosidion Ltd. Glutaminyl based dpiv inhibitors
DE602004026289D1 (en) 2003-05-05 2010-05-12 Probiodrug Ag Glutaminyl INHIBITORS
KR20110059664A (en) 2003-05-05 2011-06-02 프로비오드룩 아게 Use of effectors of glutaminyl and glutamate cyclases
GB0310593D0 (en) * 2003-05-08 2003-06-11 Leuven K U Res & Dev Peptidic prodrugs
BRPI0414497A (en) 2003-09-17 2006-11-14 Us Gov Health & Human Serv thalidomide analogs
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
KR20120007079A (en) 2003-10-15 2012-01-19 프로비오드룩 아게 Use of effectors of glutaminyl and glutamate cyclases
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6229997A (en) * 1985-04-08 1987-02-07 Sankyo Co Ltd Production of peptide having prolinamide at c terminal
AU661299B2 (en) * 1991-04-17 1995-07-20 Grunenthal Gmbh New thalidomide derivatives, method of manufacture and use thereof in medicaments
US5434170A (en) * 1993-12-23 1995-07-18 Andrulis Pharmaceuticals Corp. Method for treating neurocognitive disorders
US5443824A (en) * 1994-03-14 1995-08-22 Piacquadio; Daniel J. Topical thalidomide compositions for surface or mucosal wounds, ulcerations, and lesions
DE19613976C1 (en) * 1996-04-09 1997-11-20 Gruenenthal Gmbh Thalidomide prodrugs with immunomodulatory effects

Also Published As

Publication number Publication date
CA2256669A1 (en) 1997-12-04
CZ389398A3 (en) 1999-07-14
EP0914123A4 (en) 2000-10-11
EP0914123A1 (en) 1999-05-12
WO1997045117A1 (en) 1997-12-04

Similar Documents

Publication Publication Date Title
AU3224997A (en) Prodrugs of thalidomide and methods for using same as modulators of t-cell function
AU3941497A (en) Device for adding and dropping optical signals
AU4126897A (en) Compaction methods and apparatus
AU5265798A (en) Implementation instrument and method
AU4074597A (en) Maleimide containing formulations and uses therefor
EP0894885B8 (en) Method and apparatus for molding fiber mixture
AU4261697A (en) Compounds and methods
AU4531197A (en) An optical modulator
AU3497297A (en) Roller-ski apparatus
AU1508797A (en) Apparatus and method for protecting optical-fiber devices
AU3366497A (en) Device for sterilizising of instrument
AU1733997A (en) Blower-vacuum apparatus
AU6517798A (en) Optical disk apparatus and optical disk
AU1887297A (en) Optical modulator
AU7758698A (en) Method and apparatus for distributing long fibers
AU2858697A (en) Odour removal apparatus and/or methods
AU2500797A (en) Methods of modulating t-cell activation
EP0725396A3 (en) Optical disk and optical disk apparatus
AU8287798A (en) Adsorption apparatus and methods
AU2556195A (en) CD40 binding compositions and methods of using same
AU1699397A (en) Methods of using integrin modulators
AU9167698A (en) Mini-stencil and device for using same
AU9590898A (en) Headset apparatus
AU4748797A (en) Press apparatus for fiber-optic plug
AU2987097A (en) De-wiring apparatus